Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Net Cash Flow (2016 - 2025)

Pediatrix Medical (MD) has disclosed Net Cash Flow for 17 consecutive years, with $32.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow fell 74.95% to $32.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $145.3 million, a 13.18% decrease, with the full-year FY2025 number at $145.3 million, down 13.18% from a year prior.
  • Net Cash Flow was $32.0 million for Q4 2025 at Pediatrix Medical, down from $118.5 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $127.9 million in Q4 2024 to a low of -$854.2 million in Q1 2021.
  • A 5-year average of -$34.3 million and a median of $15.9 million in 2022 define the central range for Net Cash Flow.
  • Biggest YoY gain for Net Cash Flow was 1706.2% in 2024; the steepest drop was 1728.36% in 2024.
  • Pediatrix Medical's Net Cash Flow stood at $66.5 million in 2021, then plummeted by 75.15% to $16.5 million in 2022, then surged by 215.11% to $52.1 million in 2023, then soared by 145.6% to $127.9 million in 2024, then tumbled by 74.95% to $32.0 million in 2025.
  • Per Business Quant, the three most recent readings for MD's Net Cash Flow are $32.0 million (Q4 2025), $118.5 million (Q3 2025), and $125.8 million (Q2 2025).